IL272194A - Multispecific antibodies for use in treating diseases - Google Patents

Multispecific antibodies for use in treating diseases

Info

Publication number
IL272194A
IL272194A IL272194A IL27219420A IL272194A IL 272194 A IL272194 A IL 272194A IL 272194 A IL272194 A IL 272194A IL 27219420 A IL27219420 A IL 27219420A IL 272194 A IL272194 A IL 272194A
Authority
IL
Israel
Prior art keywords
diseases
treatment
target antibodies
antibodies
target
Prior art date
Application number
IL272194A
Other languages
English (en)
Hebrew (he)
Inventor
Dahan Rony
Salomon Ran
Original Assignee
Yeda Res & Dev
Dahan Rony
Salomon Ran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Dahan Rony, Salomon Ran filed Critical Yeda Res & Dev
Priority to IL272194A priority Critical patent/IL272194A/en
Priority to MX2022008870A priority patent/MX2022008870A/es
Priority to AU2021211962A priority patent/AU2021211962A1/en
Priority to EP21705279.4A priority patent/EP4093770A1/en
Priority to BR112022014333A priority patent/BR112022014333A2/pt
Priority to KR1020227028593A priority patent/KR20220145337A/ko
Priority to CA3167857A priority patent/CA3167857A1/en
Priority to PCT/IL2021/050064 priority patent/WO2021149053A1/en
Priority to JP2022544197A priority patent/JP7801230B2/ja
Priority to CN202180021502.0A priority patent/CN115298219A/zh
Priority to IL294931A priority patent/IL294931A/en
Publication of IL272194A publication Critical patent/IL272194A/en
Priority to US17/870,876 priority patent/US20220403043A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL272194A 2020-01-22 2020-01-22 Multispecific antibodies for use in treating diseases IL272194A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL272194A IL272194A (en) 2020-01-22 2020-01-22 Multispecific antibodies for use in treating diseases
KR1020227028593A KR20220145337A (ko) 2020-01-22 2021-01-21 질병 치료용 다중특이적 항체
AU2021211962A AU2021211962A1 (en) 2020-01-22 2021-01-21 Multispecific antibodies for use in treating diseases
EP21705279.4A EP4093770A1 (en) 2020-01-22 2021-01-21 Multispecific antibodies for use in treating diseases
BR112022014333A BR112022014333A2 (pt) 2020-01-22 2021-01-21 Anticorpos multiespecíficos para uso no tratamento de doenças
MX2022008870A MX2022008870A (es) 2020-01-22 2021-01-21 Anticuerpos multiespecificos para uso en el tratamiento de enfermedades.
CA3167857A CA3167857A1 (en) 2020-01-22 2021-01-21 Multispecific antibodies for use in treating diseases
PCT/IL2021/050064 WO2021149053A1 (en) 2020-01-22 2021-01-21 Multispecific antibodies for use in treating diseases
JP2022544197A JP7801230B2 (ja) 2020-01-22 2021-01-21 疾患の治療に使用するための多重特異性抗体
CN202180021502.0A CN115298219A (zh) 2020-01-22 2021-01-21 多特异性抗体在治疗数个疾病方面的用途
IL294931A IL294931A (en) 2020-01-22 2021-01-21 Multi-target antibodies for use in the treatment of diseases
US17/870,876 US20220403043A1 (en) 2020-01-22 2022-07-22 Multispecific antibodies for use in treating diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL272194A IL272194A (en) 2020-01-22 2020-01-22 Multispecific antibodies for use in treating diseases

Publications (1)

Publication Number Publication Date
IL272194A true IL272194A (en) 2021-07-29

Family

ID=76992165

Family Applications (2)

Application Number Title Priority Date Filing Date
IL272194A IL272194A (en) 2020-01-22 2020-01-22 Multispecific antibodies for use in treating diseases
IL294931A IL294931A (en) 2020-01-22 2021-01-21 Multi-target antibodies for use in the treatment of diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL294931A IL294931A (en) 2020-01-22 2021-01-21 Multi-target antibodies for use in the treatment of diseases

Country Status (11)

Country Link
US (1) US20220403043A1 (enExample)
EP (1) EP4093770A1 (enExample)
JP (1) JP7801230B2 (enExample)
KR (1) KR20220145337A (enExample)
CN (1) CN115298219A (enExample)
AU (1) AU2021211962A1 (enExample)
BR (1) BR112022014333A2 (enExample)
CA (1) CA3167857A1 (enExample)
IL (2) IL272194A (enExample)
MX (1) MX2022008870A (enExample)
WO (1) WO2021149053A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL286430A (en) * 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
CN120699170B (zh) * 2025-08-22 2025-11-25 中生康元生物科技(北京)有限公司 一种三特异性单链抗体及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1578199A2 (en) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
US20130245236A1 (en) 2012-03-15 2013-09-19 Richard Kroczek Antibodies to the chemokine receptor xcr1
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
KR20190014525A (ko) * 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
WO2018213747A1 (en) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. 4-1bb agonist and cd40 agonist bispecific molecules

Also Published As

Publication number Publication date
BR112022014333A2 (pt) 2022-09-13
JP7801230B2 (ja) 2026-01-16
WO2021149053A1 (en) 2021-07-29
AU2021211962A1 (en) 2022-09-15
CN115298219A (zh) 2022-11-04
US20220403043A1 (en) 2022-12-22
MX2022008870A (es) 2022-10-18
JP2023510986A (ja) 2023-03-15
KR20220145337A (ko) 2022-10-28
EP4093770A1 (en) 2022-11-30
CA3167857A1 (en) 2021-07-29
IL294931A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
IL280563A (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
IL281093A (en) Combinations for treatment of nash/nafld and related diseases
IL285269A (en) Compositions and methods for treating neurocognitive disorders
IL285270A (en) Compositions and methods for treating neurocognitive disorders
IL284125A (en) Quinoline derivatives for use in the treatment of inflammation diseases
IL263174A (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
HUE063145T2 (hu) Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra
EP3634417C0 (en) QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL285122A (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
EP3713955A4 (en) ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3959213C0 (en) PYRIMIDINE-BASED JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES
IL281244A (en) Combination therapy for the treatment of liver disease
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
IL290891A (en) Compositions and methods of treating vascular diseases
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
ZA202101587B (en) Protein for treatment of inflammatory diseases
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL310870A (en) Quinazoline compounds for treatment of disease
EP4139364A4 (en) Bispecific antibodies for treating cd47-associated diseases